Added Value of Integrated Whole-Body PET/MRI for Evaluation of Colorectal Cancer: Comparison With Contrast-Enhanced MDCT.

Abstract

The purpose of this study was to evaluate the added clinical value of PET/MRI compared with conventional contrast-enhanced MDCT (CECT) alone in the evaluation of patients with colorectal cancer. The study population comprised 51 patients with colorectal cancer who underwent (18)F-FDG PET/MRI and CECT within a 90-day interval between October 2012 and August 2013. Two reviewers in consensus evaluated whether PET/MRI added value to CECT for lesion detection and characterization and assessed whether changes in treatment strategies were made. The malignancy probability of each lesion was assessed on a 5-point scale. ROC analyses were performed with histopathologic findings, imaging, and clinical follow-up as the reference standards. Two reviewers evaluated the presence or absence of pulmonary metastatic nodules on PET/MR images that had been detected on chest CT scans. PET/MRI added value to CECT for 14 of 51 patients (27.5%) in terms of better characterization (12/51 [23.5%]) and additional detection (2/51 [3.9%]) of extracolonic lesions. The additional information from PET/MRI led to a change in treatment strategy for 11 of 51 (21.6%) patients. ROC analyses showed that PET/MRI was significantly superior to CT in depicting colorectal cancer (p < 0.05). The rate of detection of pulmonary metastatic nodules with PET/MRI was 52.9% (9/17). Integrated whole-body PET/MRI added value to CECT in the detection of metastatic lesions and characterization of indeterminate lesions, albeit with limited performance for small pulmonary metastatic nodules. The results suggest that PET/MRI may aid in the selection of more appropriate treatment strategies for patients with colorectal cancer.